SER-155
Prevention of antibiotic-resistant infections and graft-versus-host disease (GvHD) in immunocompromised patients
Key Facts
About Seres Therapeutics
Seres Therapeutics is a clinical-stage microbiome therapeutics company focused on revolutionizing patient care by harnessing the power of the human microbiome. The company achieved a landmark milestone with the FDA approval of VOWST™, the first orally administered microbiome therapeutic for preventing recurrent C. difficile infection. Seres continues to advance a diverse pipeline targeting significant unmet medical needs in infectious diseases, inflammatory bowel disease, and oncology through its proprietary microbiome platform and strategic collaborations.
View full company profileAbout Seres Therapeutics
Seres Therapeutics is a clinical-stage microbiome therapeutics company focused on revolutionizing patient care by harnessing the power of the human microbiome. The company achieved a landmark milestone with the FDA approval of VOWST™, the first orally administered microbiome therapeutic for preventing recurrent C. difficile infection. Seres continues to advance a diverse pipeline targeting significant unmet medical needs in infectious diseases, inflammatory bowel disease, and oncology through its proprietary microbiome platform and strategic collaborations.
View full company profileAbout Seres Therapeutics
Seres Therapeutics is a clinical-stage microbiome therapeutics company focused on revolutionizing patient care by harnessing the power of the human microbiome. The company achieved a landmark milestone with the FDA approval of VOWST™, the first orally administered microbiome therapeutic for preventing recurrent C. difficile infection. Seres continues to advance a diverse pipeline targeting significant unmet medical needs in infectious diseases, inflammatory bowel disease, and oncology through its proprietary microbiome platform and strategic collaborations.
View full company profile